Agenus plans to discuss a late-stage trial with the U.S. Food and Drug Administration, based on the trial data.
A preliminary analysis of the study in May had showed that the vaccine had a 146 percent increase in progression-free survival when compared with the standard-of-care.
"We are impressed by the data and look forward to feedback from the FDA regarding next steps," Roth Capital Partners analyst Joseph Pantginis wrote in a note, raising the price target on the stock to $15.
my logic is thus, for quite a few years pre-split we were stable at about $1, after the split that meant $6, so then we drop to $2 on speculative nonsense and shorting, then we bounce up to $7 on a classic pump and dump by one of the brokerages/MMs, then we wind up back at the low end under $3 after over a year of slow bleed to shake the weak hands. There has been some debt re-organizations which were positive for the company but also some dilution, maybe of about 6M new shares, or about 25% over the years. So with a great pipeline, neutral balance sheet and possibly HUGE catalysts approaching, should any of those data points be very positive, I think back to $6 is a rather conservative guess for early next year, then if buyout, asset purchase, partnership, I assume about double which would put a target of about $12 on AGEN, I think that's reasonable.
oh really? so when FDA says..."great, run a PIII CONTROLLED trial to confirm the same results, taking 3 years or so, you think the PPS will magically jump to 11-15? because that is what the FDA is going to say, run a controlled trial, until then, it's only HerpV success that will move the needle. dont be so foolish.